Skip to main content
Clinical Trials/NCT02787122
NCT02787122CompletedNot Applicable

Comparison of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia With Standard Treatment: Effects on Psychological Parameters and Rehospitalisation

Philipps University Marburg4 sites in 1 country64 target enrollmentStarted: January 1, 2014Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
64
Locations
4
Primary Endpoint
Change in Psychotic Rating Scale (PSYRATS) delusions scale

Study Overview

Brief Summary

The present study is a pilot single-blind randomized controlled therapy study. Its aim is to assess the efficacy of an emotion-focussed form of Cognitive behavior Therapy that focusses on emotional processes that are involved in the formation and maintenance of delusions such as emotional stability, emotion regulation and self-esteem.

Detailed Description

Cognitive Behavior Therapy for psychosis (CBTp) is an effective treatment for patients with psychosis. Several meta-analyses showed an effect of CBTp in addition to antipsychotic treatment of small to medium effect size with regard to positive symptoms, general psychopathology and depression. Nevertheless, present research suggests that are especially emotional processes are closely related to positive symptoms and delusions, such as negative emotions, low self-esteem, depression and anxiety, whereas present interventions of CBTp focus often especially on cognitive interventions in order to change delusions as well as more cognitive risk factors for delusions such as reasoning biases and a dysfunctional causal attribution style.

Thus, the aim of the present single-blind randomized-controlled pilot therapy study was to assess the efficacy of a new form of emotion-focussed Cognitive behavior therapy for psychosis with regard to change in positive symptoms and delusions in comparison to standard treatment.

The main hypotheses are:

- Efficacy of CBT-E: patients with schizophrenia who receive CBT-E show a more pronounced reduction of delusions (primary outcome), as well as a more pronounced reduction of positive symptoms, depression and general psychopathology, a stronger improvement in general and social functioning and will receive lower doses of antipsychotic medication (secondary outcomes) at post-treatment.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Masking Description

Blinded rating of diagnostic interviews

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of schizophrenia, schizoaffective disorder, delusional disorder or brief psychotic disorder
  • Positive and Negative Syndrome Scale score in item P1 (delusions) of at least two
  • fluent in German language
  • agree to participate
  • estimated general intelligence of at least 70 (assessed with the German Wortschatztest (MWT-B)
  • no present suicidality

Exclusion Criteria

  • acute suicidality
  • comorbid diagnosis of borderline personality disorder and/or substance use disorder in the last six month
  • intake of Benzodiazepines

Outcomes

Primary Outcomes

Change in Psychotic Rating Scale (PSYRATS) delusions scale

Time Frame: Change between assessment pre-therapy and assessment after six month of therapy

Assessment of delusion frequency, delusion distress, conviction and loss of quality of life

Secondary Outcomes

  • Change in Calgary Depression Rating Scale for Schizophrenia (CDSS)(Change between assessment pre-therapy and assessment after six month of therapy)
  • Change in Paranoia Checklist (PCL)(Change between assessment pre-therapy and assessment after six month of therapy)
  • Change in Beck Depression Inventory-II(Change between assessment pre-therapy and assessment after six month of therapy)
  • Change in Peters et al. Delusions Inventory(Change between assessment pre-therapy and assessment after six month of therapy)
  • Change in Positive and Negative Syndrome Scale (PANSS)(Change between assessment pre-therapy and assessment after six month of therapy)
  • Change in Role Functioning Scale (RFS)(Change between assessment pre-therapy and assessment after six month of therapy)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Prof. Dr. Stephanie Mehl

Prof. Dr. rer. nat.

Philipps University Marburg

Study Sites (4)

Loading locations...

Similar Trials

Pilot-trial of Emotion-focused Cognitive... | Clinical Trial